Ftse Mib
33.280,87
0,16%
DAX
19.146,17
0,76%
S&P 500
5.948,71
0,53%
NASDAQ
18.990,91
0,13%
Bitcoin
97.871,99
3,71%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Enanta Pharmaceuticals Inc (ENTA) Enanta Pharmaceuticals Inc (ENTA) Notizie

Enanta Pharmaceuticals Inc

ENTA
9,35
0,27 (2,97%)
Ultimo aggiornamento: 21:48:02
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
14/11/202422:03EDGAR2Form SC 13G/A - Statement of Beneficial Ownership by Certain..
17/10/202422:31EDGAR2Form SC 13G/A - Statement of Beneficial Ownership by Certain..
26/9/202412:00BWEnanta Pharmaceuticals Announces Positive Topline Results..
03/9/202413:00BWEnanta Pharmaceuticals to Participate in Investor..
09/8/202423:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/8/202422:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
05/8/202422:05EDGAR2Form 8-K - Current report
05/8/202422:01BWEnanta Pharmaceuticals Reports Financial Results for its..
15/7/202423:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/7/202423:30EDGAR2Form 144 - Report of proposed sale of securities
18/6/202402:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/6/202422:15EDGAR2Form 144 - Report of proposed sale of securities
29/5/202413:00BWEnanta Pharmaceuticals to Participate at the Jefferies..
08/5/202422:37EDGAR2Form S-8 - Securities to be offered to employees in employee..
08/5/202422:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/5/202413:00BWEnanta Pharmaceuticals to Participate at the JMP Securities..
06/5/202422:05EDGAR2Form 8-K - Current report
06/5/202422:01BWEnanta Pharmaceuticals Reports Financial Results for its..
30/4/202413:10BWEnanta Pharmaceuticals Announces Inducement Grants Under..
30/4/202413:00BWEnanta Pharmaceuticals Announces the Appointment of Matthew..
29/4/202413:00BWEnanta Pharmaceuticals to Host Conference Call on May 6 at..
17/4/202413:00BWEnanta Pharmaceuticals Announces Data Presentation at ESCMID..
08/3/202423:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/3/202423:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/3/202423:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/3/202423:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/3/202423:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/3/202423:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/3/202413:00BWEnanta Pharmaceuticals to Participate at Leerink Partners..
28/2/202400:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202419:11EDGAR2Form SCHEDULE 13G - Statement of acquisition of beneficial..
15/2/202402:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/2/202402:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/2/202402:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/2/202402:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/2/202402:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/2/202402:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/2/202402:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/2/202422:24EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/2/202422:05EDGAR2Form 8-K - Current report
07/2/202422:01BWEnanta Pharmaceuticals Reports Financial Results for its..
06/2/202413:00BWEnanta Pharmaceuticals to Participate at the Oppenheimer..
31/1/202413:00BWEnanta Pharmaceuticals to Host Conference Call on February 7..
26/1/202422:37EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
26/1/202422:25EDGAR2Form DEF 14A - Other definitive proxy statements
24/1/202423:23EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
11/1/202422:15EDGAR2Form SC 13G - Statement of acquisition of beneficial..
04/1/202413:00BWEnanta Pharmaceuticals to Provide Updates on its Research..
03/1/202413:00BWEnanta Pharmaceuticals to Present at the 42nd Annual J.P...
26/12/202322:06EDGAR2Form 8-K - Current report
Apertura: 9,02 Min: 8,72 Max: 9,42
Chiusura: 9,08

La tua Cronologia

NASDAQ
ENTA
Enanta Pharmaceuticals
LSE
EPRA
Amundi Epra Dr
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network